Skip to main content

Glaukos

Glaukos Corp is an American ophthalmic medical technology company developing therapies for glaucoma, corneal disorders, and retinal diseases. The company designs, manufactures, and commercializes micro-invasive glaucoma surgery devices, sustained-release pharmaceutical implants, and corneal cross-linking systems. Main revenue drivers consist of sales of the iStent family of micro-bypass stents, iDose sustained-release implants, and Photrexa corneal formulations. Glaukos serves ophthalmic surgeons, eye care clinics, ambulatory surgical centers, and outpatient hospitals across North America, Europe, and Asia-Pacific. The company holds a pioneer position as the creator and market leader of the micro-invasive glaucoma surgery segment. Headquartered in Aliso Viejo, California, Glaukos Corp is listed on the New York Stock Exchange.

5 of the funds FundTelligence covers report a position in Glaukos.

Sector
Health Care
Country
United States
Funds holding it
5
Exposure themes
Ageing & Longevity, Healthy Ageing & Function, Vision

Funds holding Glaukos

Loading...